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                                               ABBREVATIONS 
 
VAP  - Ventilator associated pneumonia 
TLC  - Total leukocyte count 
BAL - Bronchoalveolar lavage 
ETA  - Endotracheal aspiration  
EO VAP  - Early onset VAP  
LO VAP  -Late onset VAP 
MRSA  - Methicillin resistant staph. aureus 
HAP  - Hospital acquired pneumonia  
BBS  - Blind bronchial biopsy  
CPIS  -Clinical pulmonary infection score  
ABG  - Arterial blood gas 
MDR  - Multidrug resistance 
SSD  -Supraglottic secretion draining 
CASS  - Continuous aspiration of supraglottic secretions 
QEA - Quantitative culture of endo tracheal aspirate 
PTC -Protected telescopic catheter 
MV -Mechanical ventilation 
NP  -Nosocomial pneumonia 
ARDS     -Acute respiratory distress syndrome 
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INTRODUCTION  
  
Pneumonia is the second most common nosocomial infection in critically , 
affecting 27% of all critically ill patients.  Pneumonia is defined as Nosocomial when 
it occurs more than 48 hours after the patient’s admission to the hospital  and when it 
was not in incubation at the time of hospitalisation.2 Ventilator Associated Pneumonia 
(VAP) is a subset of pneumonia and the term refers to nosocomial pneumonia in a 
patient on mechanical ventilatory support (by endotracheal tube or tracheostomy) for 
greater than or equal to 48 hours. 
Ventilator-associated pneumonia (VAP) continues to be a major threat to patients 
admitted in intensive care units (ICU) and receiving mechanical ventilation (MV). 
Eighty-six percent of nosocomial pneumonias are associated with mechanical 
ventilation and are termed ventilator-associated pneumonia (VAP). 3 
A VAP arising 48 to 96 hours after tracheal intubation usually is called “early-onset 
VAP”, and the one that occurs after this period as the “late-onset VAP” .Generally, 
early-onset VAP has a better prognosis and is more likely to be caused by aspiration 
of antibiotic-sensitive bacteria colonizing the oropharynx. Late-onset VAP may be 
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caused by more unusual or multidrug-resistant (MDR) pathogens and is associated 
with greater morbidity and mortality.  
Endotracheal intubation has been identified as a risk factor for developing 
VAP.Critically ill patients who are intubated for more than 24 hours were found to be 
at 6 to 21 times higher risk of developing ventilator-associated pneumonia  and those 
patients intubated for less than 24 hours are at 3 times the risk of VAP , compared to 
non-intubated patients. Other risk factors for VAP include decreased level of 
consciousness, gastric distention, and presence of gastric or small intestine tubes, 
trauma, or COPD. VAP is reported to occur at rates of 10 to 35 cases / 1000 ventilator 
days, depending on the clinical situation. 
 Aspiration of oral and /or gastric fluids is recognized to be an essential step in the 
development of VAP. Pulmonary aspiration is increased by supine positioning and 
pooling of secretions above the ET tube cuff . Estimates of attributable mortality are 
variable,but increased duration of ventilation is a consistent finding, along with the 
corresponding increase in hospital days and cost. 
 A major component of the problem is the ineffectiveness of therapy once VAP is 
diagnosed. Brun-Buisson et al have demonstrated failure rates of 49 to 62% despite 
the use of standard antibiotic combinations. Given the burden of VAP, both physical 
and financial, and the difficulties in treatment, prevention strategies would appear to 
be of paramount importance. 
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In this study incidence , etiology-the profile of the organisms, percentage of 
EOP/LOP, underlying risk factors and their added morbidity & mortality were 
analysed.  
 
 
 
 
AIMS AND OBJECTIVES 
 
1. To study the incidence and aetiology of VAP 
2. To analyse the underlying risk factors for VAP 
3.  To study the percentage of early and late onset pneumonia in these  patients 
4.  To study the morbidity and mortality attributed by VAP 
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REVIEW OF LITERATURE 
Pneumonia is the second most common nosocomial infection in critically ill patients, 
affecting 27% of all critically ill patients1 .Severe hospital acquired pneumonia (HAP) 
continues to pose diagnostic and therapeutic challenges to the clinician. It is an 
important clinical problem because it is common, causes significant increase in 
mortality and increases duration of hospitalisation. 
The incidence of HAP has been reported to range from 4 to10 cases per 1000 
hospitalisations.3The large variation in the incidence of HAP is in part due to the 
different criteria used in the diagnosis of HAP. Previous studies have shown mortality 
rates from 8.9% to 70% with higher mortality in surgical patients, ventilated patients 
and the type of causative organism. 
Definition 
NOSOCOMIAL PNEUMONIA 
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Pneumonia, which is parenchymal lung infection, is defined as Nosocomial when it 
occurs more than 48 hours after the patient’s admission to   the   hospital and   when   
it    was   not   in incubation at   the time   of hospitalization.  Eighty-six percent of 
nosocomial pneumonias are associated with mechanical ventilation and are termed 
ventilator-associated pneumonia (VAP).VAP occurs in up to 25% of all people who 
require mechanical ventilation. 
 
Ventilator-associated pneumonia (VAP) 
Sub-type of hospital-acquired pneumonia (HAP) which occurs in people who are on   
mechanical   ventilation   through   an   endotracheal  or tracheostomy  tube for  at  
least  48  hours. VAP is a medical condition that results from   infection which floods 
the small, air-filled sac (alveoli)  in the    lung    responsible   for   absorbing  oxygen   
from   the   atmosphere. VAP    is distinguished from other kinds   of  infectious  
pneumonia   because  of  the  different  types of  microorganisms  responsible           
antibiotics   used   to  treat,  methods of diagnosis,  ultimate   prognosis,  and  effective  
preventive measures.  In the community pneumonia is most often caused by        
S.pneumoniae, H. influenzae, or    S. aureus.   However, in the hospital the   organism    
associated with pneumonia is most   often Pseudomonas, regardless of   whether or not 
the patient is ventilated.5 
The daily hazard rate for first episodes of VAP was high for the first several days 
(3.3% per day at Day 5), and then decreased to 1.3% per day after Day 15, 
documenting a dramatic decline in pneumonia over time. This is because the 
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intubation process itself contributes to the development of VAP. VAP occurring early 
after intubation typically involves fewer resistant organisms and is thus associated 
with a more favourable outcome. 
Independent  predictors of ventilator-associated pneumonia in their Cohort were a 
primary admitting diagnosis of burns (risk ratio, 5.09 [95% CI, 1.52 to 17.03]), trauma 
(risk ratio, 5.0 [CI, 1.91 to 13.11]), central nervous system disease (risk ratio, 3.40 
[CI, 1.31 to 8.81]), respiratory  disease (risk  ratio,  2.79 [CI, 1.04 to 7.51]), cardiac 
disease (risk ratio, 2.72 [CI, 1.05 to 7.01]), mechanical ventilation in the previous 24 
hours (risk ratio, 2.28 [CI, 1.11to4.68]),  witnessed  aspiration  (risk  ratio, 3.25 [CI, 
1.62 to 6.50]), and  paralytic  agents (risk ratio, 1.57 [CI, 1.03 to 2.39])  
VAP is classified in to early-onset VAP (EOP) and late-onset VAP, defined with the 
cut-off between 5 to 7 days of mechanical ventilation. 
Symptoms and signs        
People who are on mechanical ventilation are often sedated and are rarely able to 
communicate. As such, many of the typical symptoms of pneumonia will either be 
absent or unable to be obtained. The most important symptoms are fever, low body 
temp, new purulent sputum, and hypoxia (decreasing amounts of oxygen in the 
blood). 
Risk factors  6 ,7
• Elderly age 
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• H/o transfer out from IMCU 
• Witnessed  aspiration 
• Diabetes 
• Reintubation 
• Cerebral diseases 
The spectrum of cerebral disease in these patients included meningitis, 
meningoencephalitis, Parkinson’s disease, dementia and cerebral  infarction. Patients 
at risk for staphylococcal VAP include end-stage renal disease, comatose, or 
neurosurgical patients,especially if nasal colonization is documented.25
    
Pathophysiology           
VAP primarily occurs because the endotracheal or tracheostomy tube allows free 
passage of bacteria into the lower segments of the lung in a person who often has 
underlying lung or immune problems. Bacteria travel in small droplets both through 
the endotracheal tube and around the cuff.27,28 Bacteria colonize the endotracheal or 
tracheostomy tube and are embolized into the lungs with each breath. Bacteria may 
also be brought down into the lungs with procedures such as deep suctioning or 
bronchoscopy. 
Whether bacteria also travel from the sinuses or the stomach into the lungs is, 
controversial.26 However spread to the lungs from the blood stream or the gut is 
uncommon. Once inside the lungs, bacteria then take advantage of any deficiencies in 
the immune system (such as due to malnutrition or chemotherapy) and multiply. A 
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combination of bacterial damage and consequences of the immune response lead to 
disruption of gas exchange with resulting symptoms. 
The main route of VAP occurrence is aspiration of pathogenic gram-positive and 
gram-negative bacteria, and colonization on the oropharynx and gastrointestinal tract. 
Under normal conditions, the host defense, including filtration and humidification of 
air in the upper airways, epiglottic and cough reflexes, ciliary transport by respiratory 
epithelium, phagocytes in distal lung, and systemic cell mediated and humoral 
immunity, prevent bacterial invasion.    
In intensive care units, the host defenses of patients are usually distorted because of 
their underlying diseases and invasive devices that are used. Patients are not able to 
cough efficiently due to sedation or underlying disease. Also when they are intubated, 
the endotracheal tube holds the vocal cords open and facilitates aspiration. As a 
consequence, the endotracheal or tracheostomy tube allows free passage of bacteria 
into the lower segments of the lung in a person who often has underlying lung or 
immune problems. Bacteria travel in small droplets both through the endotracheal tube 
and around the cuff.                 
Once bacteria reach the distal lung, they multiply and cause invasive disease. 
Moreover, bacteria then take advantage of any deficiencies in the immune system of 
the host to continue to multiply and worsen the condition. A combination of bacterial 
damage and consequences of the immune response lead to disturbances of gas 
exchange with resulting symptoms. 
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Morbidity and mortality associated with the development of VAP is high, with 
mortality rates ranging from 20 to 41%.8   It has been shown that the development of 
VAP increases the length on the mechanical ventilator by 4 days, critical care and 
hospital lengths of stay (LOS) by 4 and 9 days, respectively and results in > $40,000 
additional costs.9
 
 
 
Microbiology 5 
The microbiologic flora responsible for VAP is different from that of the more 
common community-acquired pneumonia (CAP). In particular, viruses and fungi are 
uncommon causes in people who do not have underlying immune deficiencies.  
Though any microorganism that causes CAP can cause VAP, there are several 
bacteria which are particularly important causes of VAP because of their resistance to 
commonly used antibiotics. These bacteria are referred to as multidrug 
resistant(MDR).           
Pseudomonas aeruginosa is the most common MDR Gram-negative bacterium 
causing VAP. Pseudomonas has natural resistance to many antibiotics and has been 
known to acquire resistance to every antibiotic except for polymyxin B. Resistance is 
typically acquired through up regulation or mutation of a variety of efflux pumps 
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which pump antibiotics out of the cell. Resistance may also occur through loss of an 
outer membrane porin channel (OprD) 
Klebsiella pneumoniae has natural resistance to some beta-lactam antibiotics such as 
ampicillin. Resistance to cephalosporins and aztreonam may arise through induction 
of a plasmid-based extended spectrum beta-lactamase (ESBL) or plasmid-based 
ampC-type enzyme. 
Serratia marcescens has an ampC gene which can be induced by exposure to 
antibiotics such as cephalosporins. Thus, culture sensitivities may initially indicate 
appropriate treatment which fails due to bacterial response. 
Enterobacter as a group also have an inducible ampC gene. Enterobacter may also 
develop resistance by acquiring plasmids. 
Citrobacter also has an inducible ampC gene. 
Stenotrophomonas maltophilia often colonizes people who have endotracheal tubes or 
tracheostomies but can also cause pneumonia. It is often resistant to a wide array of 
antibiotics but is usually sensitive to co-trimoxazole. 
Acinetobacter are becoming more common and may be resistant to carbapenems such 
as imipenem and meropenem. 
Burkholderia cepacia is an important organism in people with cystic fibrosis and is 
often resistant to multiple antibiotics. 
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Methicillin-resistant Staphylococcus aureus is an increasing cause of VAP. As many 
as fifty percent of Staphylococcus aureus isolates in the intensive  care setting are 
resistant to methicillin. Resistance is conferred by the mecA gene.  
Diagnosis 10,11 
 VAP should be suspected in any person developing fever increasing numbers of 
white blood cells on blood testing, and new shadows (infiltrates) on a chest x-ray.  
Blood cultures may reveal the microorganism causing VAP. 
Diagnostic criteria           
A new and persistent (>48-h) infiltrate on chest radiograph 48 hours after admission to 
hospital not explained by other pathology such as pulmonary oedema and not deemed 
to be incubating at the time of admission into hospital, and Plus two or more of the 
three criteria 
(i)       Fever of >38.3°C, 
(ii)       Leukocytosis of >12 × 109/ml, and/or 
(iii) Purulent tracheobronchial secretions 
This criteria has sensitivity of 69% and a specificity of 75% for establishing the 
diagnosis of  VAP. 
Diagnostic strategy          
Two strategies exist for diagnosing VAP. One strategy collects cultures from the 
trachea of people with symptoms of VAP plus a new or enlarging infiltrate on chest x-
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ray. The next is more invasive and advocates a bronchoscopy plus bronchoalveolar 
lavage (BAL) for people with symptoms of VAP plus a new or enlarging infiltrate on 
chest x-ray.In both cases, VAP is not diagnosed when cultures are negative and 
another source of the symptoms is sought. 
TAs are adequate specimens when strict definitional criteria (organisms on Gram 
staining and fewer than 10 squamous epithelial cells per low-power field 
[magnification, ×100]) are followed. 
Although VAP spreads to the blood or pleural space in <10% of cases, if an organism 
known to cause pneumonia is cultured in the setting of clinically suspected 
pneumonia, treatment is warranted. Consequently, most experts recommend that two 
sets of blood cultures and a thoracocentesis for nonloculated pleural effusions of  ≥10 
mm in diameter on a lateral decubitus chest radiograph should be part of the 
evaluation of suspected VAP. 12  If the effusion is loculated, ultrasound guidance may 
be required.  
 
However, it is important to keep in mind not only that the sensitivity of blood cultures 
for the diagnosis of VAP is less than 25% but also that when positive, the organisms 
may originate from an extrapulmonary site of infection in as many as 64% of cases 
and even when VAP is present. 
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Because of the poor specificity of the clinical diagnosis of VAP and of qualitative 
evaluation of ETAs, Pugin et al. developed a composite clinical score, called the 
clinical pulmonary infection score (CPIS), based on six variables:  
(i)           Temperature,  
(ii)           Blood leukocyte count 
(iii) volume and purulence of tracheal secretion 
(iv) oxygenation, 
(v)           pulmonary radiography, and  
(vi) semi quantitative culture of tracheal aspirate. 13,14.  
The score varied from 0 to 12. A CPIS of >6 had a sensitivity of 93% and a 
specificity of 100%.
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CPIS Score 
 
            Value for score of 
Day   Parameter 
   1 point                       2 points 
 
 
1  Temp (°C)     38.5 to 38.9                     >39 or <36 
White blood cells/mm3                <4,000 or >11,000                   <4,000 or _11,000 & 
                                                                                                                                        >50% bands 
Secretions     Nonpurulent                       Purulent 
PaO2/FiO2                           <240 & no ARDS 
Chest X-ray infiltrates                Diffuse or patchy                      Localized 
3   Temp (°C)     38.5 to 38.9                        >39 or <36 
White blood cells/mm3               <4,000 or >11,000                     <4,000 or >11,000  
                                                                                                                                                                  & >50% bands 
Secretions     Nonpurulent                       Purulent 
PaO2/FiO2                           <240 & no ARDS 
Chest X-ray infiltrates                 Diffuse or patchy                      Localized 
Progression of chest X-ray infiltrates                                     Yes  
Sputum     Culture >1+                     Culture >1+ and 
                                                                                                                                         same organism on Gram stain 
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As multiple etiologies may explain why patients develop a fever and pulmonary infiltrates 
while receiving mechanical ventilation, we have to search for other infectious and non-
infectious etiologies concurrently with evaluation for VAP. The extent of this investigation is 
dictated by the clinical circumstances, including physical examination, laboratory findings, 
and the severity of illness. 
 
Evaluation for infectious (other than VAP) and non-infectious causes of fever 
                                         Action to be considered 
i. Changing and/or culturing intravenous lines 
ii. CT scan of sinuses, with fine needle aspirate if abnormal 
iii. Evaluation for venous thromboembolism 
iv. Clostridium difficile evaluation if diarrhea present 
v. Abdominal ultrasound and/or CT scan (especially in the case 
                Abnormal abdominal physical examination, abnormal liver 
                function tests, elevated lipase/amylase, or presence of 
                predisposing factors (abdominal surgery, pancreatitis, 
               gastrointestinal bleed or malignancy, or high-dose corticosteroids) 
vi. Lumbar puncture (especially in the case of a predisposing factor such as head trauma or 
neurosurgical procedure) 
vii. Drug fever  
    There is a general consensus that VAP is very likely in certain situations.  
     These circumstances are outlined below. 
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                     High probability of VAP                         
a) Radiographic evidence of cavitation or necrosis of the pulmonary 
       infiltrate, particularly if rapid and progressive 
b) An empyema with an adjacent pulmonary infiltrate 
c) Simultaneous recovery of the same microorganism from 
            respiratory secretions and pleural fluid 
d) Simultaneous recovery of the same microorganism from 
           respiratory secretions and blood, with no other source of the bacteremia 
e) Consistent histology on lung biopsy 
f) Positive Gram stain/culture on transthoracic needle aspirate 
g) Chest X ray demonstrating an air space process abutting a fissure& air bronchogram, 
especially if single 
Nonquantitative or semi quantitative airway sampling 
Gram staining and nonquantitative and semi quantitative cultures of tracheal 
secretions have the advantages of reproducibility and of requiring little technical 
expertise and no specialized equipment or technique. However, these studies add little 
to the sensitivity and specificity the clinical diagnosis of VAP, as the upper respiratory 
tract is rapidly, within hours of intubation, colonized by potential pulmonary 
pathogens, even when pneumonia is not present. Thus, if an organism is cultured or 
noted on Gram stain, one does not know if it is  
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             The  cause of the pneumonia or simply colonization.  In a study of 48  
 Patients with respiratory failure, concordance between tracheal non quqntitative                                           
cultures and cultures of lung tissue from open lung biopsy was only 40% 96in that study, of 
those patients with pneumonia on lung histology, endotracheal aspirate (ETA had a 
sensitivity of 82% but a specificity of only 27%. 
Only 15% of ETAs are adequate specimens when strict definitional criteria (organisms on 
Gram staining and fewer than 10 squamous epithelial cells per low-power field 
magnification, ×100) are followed .  
Nonquantitative and semi quantitative cultures of ETAs for the diagnosis of VAP are most 
useful if the specimen is adequate and antimicrobial therapy has not been added or changed 
in the prior 72 h. The negative predictive value of these cultures in this setting is high (94%). 
Quantitative cultures of airway specimens
To potentially improve the specificity of the diagnosis of VAP and the consequent 
unnecessary antibiotic use and its associated problems, numerous studies have investigated 
the role of quantitative cultures of respiratory secretions.  
These have included nonbronchoscopic methods such as quantitative cultures of ETAs 
(QEAs) and sampling of secretions from distal airways “blindly” via an  endobronchial 
catheter 15,16,17. Blind bronchial sampling (BBS), PSB, protected telescoping catheter (PTC), 
BAL, and protected BAL (mini-BAL) samples can be obtained via the latter method. 
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Bronchoscopic sampling methods permit quantitative cultures of PSB, PTC, and protected 
and nonprotected BAL specimens.18-21.
The PSB and PTC are double-sheathed catheters with a biodegradable plug occluding the 
distal end of the inner catheter to minimize bacterial contamination. 
 The PSB and PTC procedures involve placing the tip of the bronchoscope or “blindly  
placed” catheter next to an involved bronchial segmental orifice. With bronchoscopy, 
 direct visualization is possible.22 With a “blind” procedure, the catheter is advanced  
until resistance is met and then retracted a few centimetres. The inner catheter is then 
advanced 2 or 3 cm beyond the outer catheter, ejecting the plug. With PSB, a brush is further 
advanced and rotated several times; with PTC, a 10-ml syringe is used to perform three brief 
aspirations of secretions. BAL involves the infusion and aspiration of sterile saline through a 
flexible fiber-optic bronchoscope or “blindly placed” catheter wedged into a bronchial 
segmental orifice. Protected BAL involves a specialized balloon-tipped catheter with a distal 
ejectable plug. When performing a BAL to diagnose VAP, instillation of at least 140 ml of 
saline is required to maximize  diagnostic yield . 
If a bronchoscopically directed quantitative culture is chosen, the patient should receive 
adequate sedation, with consideration of a short-acting paralytic agent to prevent coughing 
during the procedure. The endotracheal tube must be ≥1.5 mm larger than the external 
diameter of the flexible bronchoscope. The patient should receive a fraction of inspired 
oxygen (FiO2) of 100%, and positive-end expiratory pressure should be reduced as much as 
tolerated. To maximize ventilation and minimize air trapping, the peak inspiratory flow 
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should be decreased to ≤60 litres/min, the respiratory rate set between 10 and 20 breaths/min, 
and the peak inspiratory pressure alarm increased. 
The patient should be carefully monitored throughout the procedure, with particular attention 
to exhaled tidal volume, peak inspiratory pressure, oxygen saturation, the electrocardiogram, 
and vital signs. Secondary hypotension should be anticipated, and appropriate intravenous 
fluids and vasopressors should be available for immediate administration . 
The sampling area should be chosen based on the location of the infiltrate on chest X ray or 
CT scan. This typically corresponds to the bronchial segment with purulent secretions and/or 
where endobronchial abnormalities are maximal, which can be clues in the setting of diffuse 
pulmonary infiltrates or minimal changes in a previously abnormal chest X ray . When in 
doubt, sample the posterior right lower lobe, since autopsy studies have indicated that VAP 
frequently involves this area. 
 The presence of more than 1% epithelial cells or 10 epithelial cells per low-power field 
(magnification, ×100) in bronchoscopic or “blind” BAL, PSB, PTC, or bronchial sampling 
suggests heavy oropharyngeal colonization. Returns of <10% of the instilled BAL fluid are 
probably not representative of the lower respiratory tract .  For QEAs, the same criteria 
mentioned above for nonquantitative and semi quantitative cultures of an ETA should be For 
each of the quantitative culturing methods, threshold values have been derived and are 
expressed in CFU per millilitre. If the number of CFU/ml is equal to or exceeds the threshold 
values for the particular technique, a diagnosis of pneumonia is made. Threshold values often 
employed for diagnosing pneumonia by quantitative cultures are ≥105 to 106, ≥104, and ≥103 
CFU/ml for QEA, bronchoscopic BAL, and PSB, respectively, with ≥105 CFU/ml being the 
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most widely accepted value for QEA . For “blind” distal sampling, the thresholds are ≥103 
CFU/ml for PSB and mini-BAL and ≥104 CFU/ml for cultures obtained with BBS and 
unprotected utilized. 
Treatment 
Treatment must be obtained quickly and treatment initiated without delay .Principles to apply 
when choosing appropriate therapy for VAP include knowledge of organisms likely to be 
present, local resistance patterns within the ICU, a rational antibiotic regimen, and a rationale 
for antibiotic de-escalation or stoppage. Early effective therapy for VAP is associated with 
reduced mortality. Luna et al. demonstrated that inadequate therapy during the initial 48 h, 
despite provision of adequate therapy after BAL results, was associated with a mortality rate 
of 91% . When empirical therapy was appropriate, mortality rates were much lower (38%). 
Delays in the administration of appropriate antibiotic therapy for VAP have been associated 
with excess mortality . In one study, a delay in appropriate therapy for 24 h or more was 
associated with a 69.7% mortality, compared to 28.4% in patients treated   without    the  
delay 
 (P < 0.001).23,24
A low threshold for suspicion of VAP is needed when a patient's clinical course deteriorates. 
The day 1 CPIS can be useful, especially when combined with quantitative cultures. The 
choice of which quantitative culture methodology to use is an open debate. However, 
diagnostic cost favours QEA, which can also be implemented as a surveillance technique. 
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Antibiotic administration should be promptly initiated when VAP is suspected and 
quantitative cultures obtained and should be broad in coverage. Knowledge of local 
antibiograms should guide the choice of antibiotics, in addition to likelihood of organisms 
(early- or late-onset VAP). For patients already on antibiotics at the time of suspected VAP, 
the clinician should choose antibiotics from different classes, as it is likely that resistance to 
“in-use” antibiotics has developed. 
Assessment of the likelihood of VAP by day 3 is needed to decide whether antibiotics should 
be continued. The assessment should include a repeat CPIS, as the change in CPIS can guide 
clinical decisions, even stoppage of antibiotics. Assessment of quantitative culture results and 
sensitivities at this juncture is prudent, as it may permit early antibiotic de-escalation by 
choosing a more narrowly focused agent(s). Monotherapy may be appropriate in many 
instances of VAP and should reduce the incidence of drug resistance. A change to 
monotherapy may be possible in a responding patient where organism sensitivity results 
permit. A short course (6 to 8 days) can be administered to patients with VAP but is 
dependent on the patient physiologic response to treatment along with which organisms have 
been recovered 
Treatment of VAP should be matched to known causative bacteria. However, when VAP is 
first suspected, the bacteria causing infection is typically not known and broad-spectrum 
antibiotics are given (empiric therapy) until the particular bacterium and its sensitivities are 
determined. Empiric antibiotics should take into account both the risk factors a particular 
individual has for resistant bacteria as well as the local prevalence of resistant 
microorganisms. If a person has previously had episodes of pneumonia, information may be 
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available about prior causative bacteria. The choice of initial therapy is therefore entirely 
dependent on knowledge of local flora and will vary from hospital to hospital. 
ATS has recently published guidelines to guide empirical antibiotic choices .These guidelines 
are divided into those for patients at risk for VAP caused by multidrug-resistant organisms 
and those for patients without such risk. Risk factors for multidrug-resistant organisms 
include prior antimicrobial therapy in the preceding 90 days, current hospitalization 
exceeding 5 days (not necessarily ICU days),  high frequency of resistance in the community 
or local hospital unit, and immunosuppressive disease and/or therapy and ventilation for 
more than five days,  Residence in a nursing home, Treatment in a haemodialysis clinic. .  
People who do not have risk factors for MDR organisms may be treated differently 
depending on local knowledge of prevalent bacteria.  
 In the absence of risk factors for multidrug-resistant bacteria, the clinician should choose 
empirical therapy for Streptococcus pneumoniae, Haemophilus influenzae, 
methicillin-sensitive Staphylococcus aureus, and antibiotic-sensitive gram-negative 
enteric organisms. Antibiotic choices include ceftriaxone, quinolones (levofloxacin, 
moxifloxacin, or ciprofloxacin), ampicillin/sulbactam, or ertapenem.  
Antibiotic choice can be tailored to the pathogens’ last sensitivity report should QEA 
surveillance cultures be obtained twice weekly and should the growth level exceed 100,000 
CFU/ml. 
When risk factors for multidrug-resistant organisms are present, the clinician must consider 
not only the organisms listed above but also Pseudomonas aeruginosa, Klebsiella, 
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Enterobacter, Serratia, Acinetobacter, Stenotrophomonas maltophilia, Burkholderia cepacia, 
and methicillin-resistant S. aureus. Empirical therapy is broadened to include  
(i) Either an antipseudomonal cephalosporin (cefepime or ceftazadime), an 
antipseudomonal carbepenem (imipenem or meropenem), or a β-lactam/β-
lactamase inhibitor (pipercacillin-tazobactam) plus 
(ii) An antipseudomonal fluoroquinolone (ciprofloxacin or levofloxacin) or an 
aminoglycoside (amikacin, gentamicin, or tobramycin) plus linezolid or 
vancomycin30.  
Possible empirical therapy combinations include (but are not limited to): 
• Vancomycin/linezolid and ciprofloxacin, 
• Cefepime and gentamicin/amikacin/tobramycin 
• Vancomycin/linezolid and ceftazidime 
• Ureidopenicillin plus β-lactamase inhibitor such as piperacillin/tazobactam or 
ticarcillin/clavulanate 
•  Carbapenem (e.g., imipenem or meropenem) 
Therapy is typically changed once the causative bacteria are known and continued until 
symptoms resolve (often 7 to 14 days). 
There is ongoing research into inhaled antibiotics as an adjunct to conventional therapy. 
Tobramycin and polymyxin B are commonly used in certain centers but there is no clinical 
evidence to support their use. 
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PREVENTION  
General measures 
Prevention of VAP involves limiting exposure to resistant bacteria, discontinuing mechanical 
ventilation as soon as possible, and a variety of strategies to limit infection while intubated. 
Resistant bacteria are spread in much the same ways as any communicable disease. Proper 
hand washing, sterile technique for invasive procedures, and isolation of individuals with 
known resistant organisms are all mandatory for effective infection control. A variety of 
aggressive weaning protocols to limit the amount of time a person spends intubated have 
been proposed. One important aspect is limiting the amount of sedation that a ventilated 
person receives. 
Specific measures  
The ability to prevent EOP is clearly greater than that of late-onset VAP. Many of the best-
validated strategies for VAP prevention, including CASS, are for EOP.EOP can also be 
prevented by other strategies, such as by simply administering ventilation with patients in the 
semirecumbent position,prophylactic short course,  high dose antibiotic therapy, and others 
Having the ability to prevent late-onset VAP  is much more difficult. The pathogenesis is 
different than EOP. 
Antibiotic selective pressure and cross infection are themes that common to late-onset VAPs. 
Many late-onset VAPs, especially Pseudomonas,occurwithout preceding oropharyngeal or 
gastric colonization the target of many prevention strategies. 
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No prevention strategy has shown a clear-cut benefit for late-onset VAP. The best prevention 
strategies may actually be an accurate diagnosis of EOP and avoidance of antibiotics as much 
as possible31. 
                   
 
 Potential strategies to prevent VAP 
I. Prior to intubation  
(i) Address reversible causes of respiratory failure-bronchospasm 
,analgesia,sedation 
(ii) Non invasive mechanical ventilation 
 
II. Process of intubation 
1) Avoid gastric distension 
2) Oroendotracheal  route 
 
III. After intubation(data supported) 
1) Oral route gastric tube                          
2) Head end elevation 30-45 degrees 
3) Good hand hygiene 
4) Closed suctioning 
5) Continuous sub glottis suctioning 
6) Rotational beds 
7) Chlorhexidine oral rinse in cardiac patients 
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8) Minimise sedation 
9) Weaning protocols 
 
IV. After intubation(controversial) 
1) Early vs late enteral nutrion 
2) Selective gut decontamination 
3) Rotational antibiotic schema 
4) Antibiotic impregnated endotracheal tube 
 
 
Non-invasive mechanical ventilation (NIV) has been associated with more favourable 
outcomes (mortality and morbidity) in comparison to endotracheal tube placement in patients 
with acute exacerbations of chronic obstructive pulmonary disease or acute pulmonary 
oedema .32,-35
 The incidence of nosocomial pneumonia was reduced in the group randomized to NIV 
Furthermore, immunocompromised patients with bilateral infiltrates also benefited from NIV 
over invasive mechanical ventilation (IMV) with regard to both mortality and morbidity. 34  
Once the decision to intubate is made, the practice of VAP prevention should be directed at 
reducing colonization and aspiration (volume of organisms presented to the lungs). This 
begins with choosing the oral route of intubation and focusing on minimizing the duration of 
mechanical ventilation (DOMV).  
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Oral intubation is preferred over nasal intubation, as the latter has been associated with both 
VAP and sinusitis, with the same bacteria identified in both. Rouby et al., demonstrated a 
significant reduction in nosocomial sinusitis when patients are orally cannulated with 
endotracheal and gastric tubes.35
Holzapfel et al. have linked the reduction in nosocomial sinusitis to a reduction in VAP.36
Furthermore, the clinician must give careful attention to the mundane and seemingly small 
interventions, such as regularly assessing endotracheal cuff pressure, performing 
endotracheal suctioning, draining ventilator tube condensate, avoiding gastric overdistention, 
avoiding the supine position, avoiding unnecessary ventilator circuit changes, application of 
heat and moisture exchangers (HMEs) when appropriate, minimizing out-of-ICU transports, 
and regular hand cleaning with soap or alcohol disinfectant.  
Maintaining cuff pressure of endotracheal tubes at ≥20 mm Hg reduces nosocomial 
pneumonia, presumably by minimizing the passage of oropharyngeal contents into the 
trachea. 37
The duration of intubation directly affects the likelihood of VAP, which is more evident in 
patients with ICU LOS exceeding 5 days. Fagon et al. suggested that the incidence of VAP 
increases by 1% per day of IMV . However, Cook et al. found that the incidence per day 
varies over time, with 3% per day during first 5 days of IMV, 2% for the second 5 days, and 
1% for the subsequent 5-day period 38. This observation is supported by Ibrahim et al., who 
identified an incidence rate of VAP of 11.5%, 56% of which were early onset (≤5 day) 39. 
Hence, the greatest attack rates appear to be during the initial days of mechanical ventilation. 
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Additionally, significant risk factors for early-onset VAP include cardiopulmonary 
resuscitation and continuous sedation.40
Continuous sedation is more often administered in the acute phase of an illness. In addition to 
treating the primary cause of respiratory failure, the DOMV can be reduced through judicious 
use of sedatives and analgesics.  
Studies by Brook et al. and Kress et al. have demonstrated that protocols for sedative and 
analgesic administration with the goal of minimizing constant infusions led to reduced 
DOMV.41,42  Furthermore, daily interruption of sedation results in a reduced incidence of 
intensive care unit complications, in which VAP was included. 43,44.
 Weaning protocols have also resulted in reduced DOMV, whether respiratory therapist 
initiated or not.45,46
Patients should be cared for in the semi recumbent position to reduce the extent of aspiration, 
especially when receiving enteral feeds.  
Radionuclide studies reveal increased tracheal penetration of gastric contents when intubated 
patients are supine 47   Drakulovic et al. found that the simple elevation of the head of bed to 
45° results in dramatic reductions in VAP incidence and a trend toward reduced mortality 48. 
Nonetheless, a recent survey by the University Hospital Consortium revealed that compliance 
with the simple and no-cost intervention of elevating the head is woefully low, and a study by 
Heyland et al. revealed that the head of bed is on average elevated to 29° and not 45°. 49 . 
Compared to supine positioning, studies have shown that simple positioning of the head of 
bed to 30° or higher significantly reduces gastric reflux and VAP (8% versus 34%, 
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respectively). Kinetic bed therapy has also led to a reduction in the incidence of VAP.50,51 
However, this is costly and has not been directly compared to head-of-bed elevation, a no-
cost option. 
Some VAP is contracted from inhalation of bacteria through the ventilator circuit and may be 
a result of contaminated aerosols, condensate, or suction catheters. Traditionally, ventilator 
circuit changes have been on a regular schedule and often daily. However, the data 
examining this practice reveal that there is no benefit to changing the circuit on a regular 
basis, and the present recommendations are to change the circuit when soiled .52  Such a 
practice would likely reduce the rate of accidental spillage of condensate into the airway. 
 As heated humidifiers enhance the amount of condensate, attention has been focused on 
HMEs. These devices have led to a reduction in VAP, albeit small, and should be used in 
patients without significant secretions or concern over the risk of obstruction.53,54. While 
changing the HME less frequently than every 48 h may lead to further reductions in VAP, 
care must be taken to carefully monitor for trapped secretions and subsequent airway 
obstruction or increments in the work of breathing55. 
Endotracheal suctioning of intubated patients can be performed through an open or closed 
system. In theory the closed system could reduce the incidence of VAP, but in practice this 
has not been demonstrated .56,57  Cost analysis favours the closed system, as the enveloped 
catheter can be reused for suctioning and needs to be changed only when dysfunctional. 58 
However, respiratory therapists have voiced concerns over residue build-up within the lumen 
of the endotracheal tube. 
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As most VAP follows from aspiration of oropharyngeal secretions, attention to proper cuff 
inflation pressures and endotracheal suctioning can affect the volume presented to the 
trachea.  
The application of continuous suction of subglottic secretions through specialized 
endotracheal tubes will reduce the incidence of VAP .59,60  Surprisingly, this was not 
associated a reduction in mortality, ICU LOS, or duration of mechanical ventilation. 
While studying the application of continuous subglottic suctioning, Rello et al. noted a trend 
of increased VAP in patients with endotracheal cuff pressures of <20 cm H2O61. Hence, it is 
recommended not only to assess cuff pressure for tracheal ischemia (which occurs when 
pressure exceeds 30 cm H2O) but also to ensure that adequate cuff pressure (>20 mm Hg) is 
present.  
American and Canadian guidelines strongly recommend the use of supraglottic secretion 
drainage (SDD) Special tracheal tubes with an incorporated  suction lumen as the EVAC 
tracheal tube form Covidien / Mallinckrodt can be used for that reason. studies on the use of 
special ET tubes which remove secretions pooled above the cuff with continuous suction 
decrease VAP by 45 to 50 % (Cook, De Jonghe, Brochard, & Brun-Buisson, 1998; Valles et 
al., 1995). specialized endotracheal tubes that allow continuous aspiration of subglottic 
secretions.  
The endotracheal tube itself is a reservoir for gram-negative bacteria. The buildup of a 
biofilm within endotracheal tubes occurs frequently. One study demonstrated that 84% of 
endotracheal tubes examined had a biofilm 62. As documented by Inglis et al., this biofilm is 
37 
 
heavily laden with bacteria, usually gram-negative organisms.63,64   At present, ongoing 
studies are directed at either eliminating this biofilm or reducing the bacterial load associated 
with it.  
New cuff technology based on polyurethane material in combination with subglottic drainage 
(SealGuard Evac tracheal tube from Covidien/Mallinckrodt) showed significant delay in 
early and late onset of VAP.[2]A recent clinical trial indicates that the use of silver-coated 
endotracheal tubes may also reduce the incidence of VAP. 
 
 
Oral decontamination with chlorhexidine has been shown to reduce the incidence of VAP in 
patients undergoing cardiac surgery, presumably by reducing oropharyngeal colonization.65 
Furthermore, numerous studies with oral decontamination antibiotic pastes alone or co 
administered with systemic antibiotics have shown a reduction in early VAP.66-70 Two meta-
analyses have suggested better results with oral decontamination alone than with the 
combination of oral and systemic prophylaxis. 71,72 With either approach, however, concern 
over the emergence of antibiotic-resistant organisms has tempered use, as has the labor 
intensity required to apply these regimens at the bedside. This is particularly true in ICUs 
housing organisms with high antibiotic resistance rates. 73-76 While often recommended, it 
appears not to be routinely practiced. Two recent studies will further the debate, as they 
demonstrated significant reductions in VAP and mortality with selective decontamination of 
the digestive tract. 77,78 These two studies were performed under conditions where selective 
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decontamination of the digestive tract is most effective, i.e., surgical intensive care units 
housing patients less likely to be colonized with resistant bacteria. 
Gastric volumes and acidity affect the incidence of VAP. Reducing the acidity of gastric 
secretions and feeding will reduce bacterial overgrowth. However, in high-risk patients 
(ventilated for >48 h and coagulopathic), the risk of bleeding outweighs the risk of VAP from 
pH-modifying agents.79  Hence, it is difficult to recommend against H2 blockers or proton 
pump inhibitors. Sucralafate may indeed be superior from the viewpoint of VAP, but it is less 
effective with regard to prophylaxis of gastrointestinal bleeding,  and thus it use is not 
warranted over H2 blockers or proton pump  inhibitors.80-82.
Multiple studies have examined post pyloric versus gastric feedings with regard to incidence 
of aspiration and development of VAP. These studies were small and inconclusive. In a 
meta-analysis, post pyloric feedings reduce the incidence of VAP and increased the nutrition 
delivered. 83However, no single trial demonstrated that post pyloric tube feedings prevent 
VAP. The improved delivery of nutrition was likely the result of decreased gastric residual 
assessments and consequently fewer stoppages in continuous tube feedings. 
A recent publication favoured a delay of greater than 5 days before initiating tube feedings, 
as the incidence of VAP was reduced 84. Further data are needed to unconditionally embrace 
this practice. 
Preventing Multidrug Resistance 
Antibiotic cycling remains controversial. Employing a rotational schedule for empirical 
antibiotic administration for suspected VAP may indeed lead to a reduced incidence of 
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resistant organisms. 85-87  While such a strategy may not reduce the incidence of VAP, 
reductions in mortality may be seen.87 This is likely a result of changes in resistance patterns 
resulting in a higher likelihood of choosing appropriate antibiotic regimens 88. Because 
rotational schedules have primarily targeted reducing the resistance of gram-negative 
organisms, we do not know the impact of rotating antibiotics against gram-positive 
organisms, such as methicillin-resistant S. aureus. Furthermore, the frequency with which 
to rotate antibiotics remains unclear, as monthly and quarterly regimens have been assessed 
with documented successes. 87   Furthermore, the probability of antibiotic cycling leading to a 
reduction in antimicrobial resistance is low as determined through mathematical modelling. 
89 At this juncture, it is premature to recommend rotating antibiotics or a rotational schema. 
Multidrug resistance can also be reduced when patient-antibiotic PK/PD characteristics are 
accounted for. Early eradication minimizes the opportunity for a population of organisms to 
develop resistance. Peak concentrations for aminoglycosides 10-fold greater than MIC appear 
to inhibit the emergence of resistant organisms. 90,91   When choosing fluoroquinolones, 
resistant organisms are less likely to be seen when the 24-h area-under-the-curve/MIC levels 
are >100 for gram-negative bacteria and >40 for gram-positive bacteria.92 Changes in 
medication frequency or infusion rates can increase the time that the antibiotic concentration 
exceeds the MIC. For β-lactams, monobactams, glycopeptides, and cabapenems this can be 
important in enhancing bactericidal activity, again reducing opportunities for resistant 
organisms to emerge.93
In summary, several opportunities to reduce the incidence of VAP are available to the 
clinician. Many are no-cost or minimal-cost interventions and should be implemented as part 
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of routine care protocols. Care of the critically ill should be directed at applying interventions 
that reduce mortality, minimize morbidity, shorten the length of stay, and reduce cost. 
Reducing VAP through the simple measures outlined does exactly that. We recommend that 
the clinician's practice include non-invasive mechanical ventilation over intubation when 
appropriate, oral intubation when an endotracheal tube is necessary, orogastric over 
nasogastric tubes, elevation of the head to at least 30°, minimization of sedation, 
administration of a proton pump inhibitor when prophylaxis is indicated, a frequency of 
ventilator tubing changes at 7 days or when soiled, avoidance or elimination of endotracheal 
tube leak, good technique in removal of condensate, and of course excellent hand hygiene. At 
this time we do not support the routine use of endotracheal tubes with subglottic suction 
capabilities, rotational beds, in-line suction systems, rotational antibiotic schemes, or 
selective gut decontamination. 
Strategies and a more thorough discussion on prevention are within the ATS/Infectious 
Disease Society of America statement and papers by Kollef and by Dodek et al94 Zack et al. 
have demonstrated that a multifaceted and multidisciplinary approach to VAP prevention can 
indeed reduce the incidence. 95 Success is dependent upon persistent attention to detail, high 
compliance rates, and a champion. 
Current standards related to prevention of VAP (The Ventilator Bundle) 
O The ventilator bundle is a group of evidence-based practices that, when  
implemented together for all patients on mechanical ventilation, result in dramatic  
reductions in the incidence of ventilator-associated pneumonia. The ventilator  
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bundle has four key components:  
(i) Elevation of the head of the bed to between 30 and 45 degrees,  
(ii) Daily “sedation vacation” and daily assessment of readiness to extubate, 
(iii)  Peptic ulcer disease (PUD) prophylaxis, and  
(iv) Deep venous thrombosis (DVT) prophylaxis (unless contraindicated). 
Passive humidifiers or heat moisture exchangers are preferred to reduce colonization of the 
ventilator circuit. Ventilatory-circuit condensation should be prevented from entering the 
endotracheal tubes and any inline nebulizer. 
Studies comparing H2 receptor blockers with sucralfate have shown conflicting results, with 
a trend toward a reduction of VAP with the use of sucralfate.11,12,13  These benefits were 
most notable with late-onset VAP. Use of noninvasiveventilation in the subgroup of 
respiratory failure patients with chronic airflow limitation is the prevention of VAP. 
Epidemiology and prognosis 
It has been shown that VAP prolongs both the duration of mechanical ventilation, the 
duration of ICU stay, and hospital length of stay. Moreover, patients who develop VAP have 
a higher mortality and crude hospital cost compared to patients without VAP. 
Because respiratory failure requiring mechanical ventilation is itself associated with a high 
mortality, determination of the exact contribution of VAP to mortality has been difficult. As 
of 2006, estimates range from 33% to 50% death in patients who develop VAP. Mortality is 
more likely when VAP is associated with certain microorganisms (Pseudomonas, 
Acinetobacter, Stenotrophomonas maltophilia), blood stream infections, and 
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ineffective initial antibiotics. VAP is especially common in people who have acute 
respiratory distress syndrome (ARDS). 
Studies have provided different results when determining attributable mortality, in part 
because of very different populations (less-acute trauma patients, acute respiratory distress 
syndrome [ARDS] patients, and medical and surgical ICU patients) and in part as a result of 
variances in appropriate empirical medical therapy during the initial 2 days.  Beyond 
mortality, the economics of VAP include increased ICU lengths of stays (LOS) (from 4 to 13 
days), and incremental costs associated with VAP have been estimated at between $5,000 
and $20,000 per diagnosis. 
 
 
     Limitations 
 
i. The number of patients who had VAP was small  
ii. Quantitative cultures of sputum and endotracheal aspirate  specimens were not done, 
and  
iii. The method of obtaining specimens was from the endotracheal aspirate and not by 
BAL /PTC. 
iv. The systemic signs of pneumonia such as fever, tachycardia, and leukocytosis are 
nonspecific; they can be caused by any state that releases the cytokines interleukin-1, 
interleukin-6, tumor necrosis factor alpha, and gamma interferon . Examples of such 
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conditions include trauma, surgery, the fibro proliferative phase of ARDS, deep vein 
thrombosis, pulmonary embolism, and pulmonary infarction. 
v. Although a normal chest radiograph makes VAP unlikely, in one study of surgical 
patients, 26% of opacities were detected by computed tomography (CT) scan but not 
by portable chest X ray.  
In addition, asymmetric pulmonary infiltrates consistent with VAP can be caused by 
numerous non-infectious disorders, including atelectasis, chemical pneumonitis, asymmetric 
cardiac pulmonary edema, pulmonary embolism, cryptogenic organizing pneumonia, 
pulmonary contusion, pulmonary haemorrhage, drug reaction, and asymmetric ARDS. The 
overall radiographic specificity of a pulmonary opacity consistent with pneumonia is only 
27% to 35%. 
vi. The above study based on clinical symptoms and tracheal culture has low sensitivity and 
specificity as the upper respiratory tract is rapidly, within hours of intubation, colonized by 
potential pulmonary pathogens, even when pneumonia is not present.  
Thus, if an organism is cultured or noted on Gram stain, one does not know if it is the cause 
of the pneumonia or simply colonization. In a study of 48 patients with respiratory failure, 
concordance between tracheal non quantitative cultures and cultures of lung tissue from open 
lung biopsy was only 40%. 
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MATERIALS AND METHODS 
1. STUDY POPULATION: 
A total of 50 patients satisfying all inclusion & exclusion   criteria were  included for the 
study from the population of patients who underwent mechanical ventilation in our medical 
intensive care unit & toxicology . written consent was obtained from all patients  attenders in 
the study after clearly explaining the study procedure .The patients were visited on day 3 of 
mechanical ventilation for diagnosis of VAP according to the clinical criteria and also on day 
7 for classifying into EOP & LOP.  
 2. STUDY SETTING: 
Patients admitted in imcu and toxicology underwent ventilation > 48 hrs in  
MMC govt general hospital. 
3. COLLABORATION DEPARTMENT: 
 IMCU & toxicology 
             Microbiology dept. 
4. ETHICAL APPROVAL: 
 Institutional ethical committee approved the study 
5. STUDY DURATION: 
  The study was conducted for a period from jan 2008 to jun 2009.  
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6. STUDY DESIGN: 
Cross sectional study to evaluate the incidence of ventilation associated  pneumonia and also 
the percentage of EOP & LOP.   
INCLUSION CRITERIA: 
Patients who were admitted and underwent mechanical ventilation for 48 hrs in medical 
intensive care and toxicology unit age > 12 yrs. 
EXCLUSION CRITERIA: 
• Age < 12 yrs  
• Patients who have got lower respiratory tract infection on admission  
Pulmonary tuberculosis  
COPD  
ARDS 
Bronchial asthmatics 
METHODS AND MATERIALS: 
Patients who were admitted in IMCU & toxicology had underwent mechanical ventilation for 
48 hrs were visited and the clinical criteria was applied to diagnose VAP. 
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Those patients who developed new and persistent infiltrates on CXR   after 48 hrs of 
mechanical ventilation and developing fever > 38.3, purulent tracheoseophageal aspirate and 
with total leukocyte count > 10000. 
The patients were diagnosed to have VAP based on the following criteria for VAP: 
The presence of persistent and new chest x – ray infiltrates after 48 hrs of ventilation plus any 
two of the following three 
  1. fever > 38.3   C 
  2. total leukocyte count > 10,000 
  3. Purulent tracheal aspirate  
The organism that caused VAP was defined as the organism which was  Isolated from the 
sputum or endotracheal aspirate which was sent for culture and  sensitivity.  The day of onset 
of VAP was noted to classify into EOP (5 – 7 days) or LOP  (>7 days) by revisiting the 
patients on day 7. 
Death was defined as pneumonia related if the pneumonia was designated as the underlying 
or immediate cause of death or was determined to have a major contributing role in the cause 
of death. 
The underlying risk   factors for these patients were noted and revisiting of patients were 
done regularly to know the outcome of the patients and their total duration of mechanical 
ventilation and their stay in ICU.  
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STATISTICAL ANALYSIS: 
Excel and SPSS 12 were used for data analysis 
CONFLICT OF INTEREST: none  
FINANCIAL       SUPPORT        : Nil 
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RESULTS AND OBSERVATIONS 
 
The incidence of VAP in our study is 44% 
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                                                                               TABLE 2 
AGE DISTRIBUTION OF CASES
S.No. Age group Number Percentage 
1. 0 – 30 7 31.81% 
2. 31 – 60 13 59.09% 
3. >60 2 9.10% 
 
 
Majority of patients were in the group of 31 – 60 years.  The number of           
people between 31 – 60 years accounts for 59%. 
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                                                          TABLE 3 
SEX DISTRIBUTION 
S.No. Sex Frequency Percentage 
1. Male 14 63.64% 
2. Female  8 36.36% 
 
 
 
Incidence of VAP was more in male compared to females in our study.  14 out of     22 
were males. 
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       TABLE 4 
METHOD OF INTUBATION 
 Frequency Percentage 
Elective 50 50% 
Emergency 50 50% 
 
 
 
In our study 50% of patients underwent elective and 50% patients underwent emergency 
distribution. 
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   TABLE 5 
X-RAY FINDING IN THE CASES 
S. No. Lobar 
distribution 
Frequency Percentage 
1. Right side 15 68.18% 
2. Left side 3 13.63% 
3. Bilateral 4 18.18% 
 
 
In majority of over cases, the CXR infiltrate was in the Right lung which comes 
around 68.2%. 
 
18% 
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TABLE 6 
EARLY Vs LATE VAP 
 Frequency Percentage 
Early  8 36.4% 
Late 14 63.4% 
 
 
 
The percentage of EOP & LOP is 36.4% and  63.4% respectively. 
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                                                          TABLE 7 
PROFILE OF ORGANISM 
 Frequency Percentage 
Gram Negative 13 59.0% 
Gram Positive 5 22.7% 
Polymicrobial 4 18.3% 
 
 
           The percentage of gram negative organisms (59.9%), gram positive (22.7% ) & 
polymicrobes (18.3%) 
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TABLE 8 
 
AETIOLOGY 
S. No. Micro-organism Frequency Percentage 
1. Pseudomonas 7 31.8% 
2. MRSA 5 22.7% 
3. Polymicrobial 4 18.4% 
4. Acinetobacter 3 13.6% 
5. Klebsiella 2 9.0% 
6. Proteins  1 4.5% 
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The organisms found in cultures in the descending frequency were pseudomonas, MRSA, 
Polymicrobial followed by acinetobacter. 
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                                                          TABLE 9 
AGE DISTRIBUTION AND OUTCOME  
Death Recovery 
Age 
Number % Number % 
0 – 30 Years 2 14.28% 3 37.5% 
30 – 60 years 10 71.42% 5 62.5% 
>60 years 2 14.28% 0 0% 
 
 
The mortality rate was high in patients of age group 30 – 60 years which accounts for 71.4% 
of total deaths. 
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TABLE 10 
 
 
 
RISK FACTORS  
S.No. Risk Factor Frequency Percentage 
1 Diabetes 8 50% 
2 H/o Transfer out 2 12.5% 
3 Elderly 2 12.5% 
4 Shock in the first two days 
of admission 
2 12.5% 
5 HIV 2 12.5% 
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 The major risk factor found in our study was Diabetes Mellitus. 
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                                                        TABLE 11 
 
DURATION OF STAY IN ICU 
VAP N-VAP  
S.No Days Frequency % Frequency % 
1 <10 4 18.2% 23 82.14% 
2 10 – 20 7 31.8% 5 17.86% 
3 21 – 30 6 27.3% - - 
4 >30 5 22.7% - - 
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 The mean duration of stay in the hospital who developed VAP was 10 – 
20 days without VAP gp is < 10 days. 
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DISCUSSION 
1. Incidence 
Incidence of VAP in our govt.general hospital is 44% ,where as in united states VAP occurs 
in up to 25% of all people who require mechanical ventilation. 
2. Age distribution 
The percentage of patients with VAP in different age groups is as follows 
        <30years- 31.81% 
         31-60years- 59.99% 
        >60years-9.1%  
The higher incidence in the age group (31-60) can be attributed to more number of patients 
getting admitted &undergoing ventilation in this age group.It may also be due to their 
associated co morbid conditions. 
3. Sex distribution 
In our govt.hospital two third of the cases were males (63.6%) remaining cases one third 
were (36.4%) females. 
4. Method of intubation 
There is equal incidence of VAP in both elective& emergency intubation. 
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5. Chest X-ray infiltrates 
In our study 68.2%of patients had infiltrates in right lung.13.6%of patients in the left lung 
18.2% bilaterally .  The higher percentage of infiltrates in the right lung lower lobe is 
because of aspiration being the most common precipitating factor for VAP.  Autopsy studies 
by Marquette, C. H., M. C. Copin, F. Wallet, R. Neviere, F. Saulnier, D. Mathieu, A. 
Durocher, P. Ramon, and A. B. Tonnel. 1995 have indicated that VAP frequently involves 
posterior right lower lobe. 
6.  Types of VAP 
The percentage of patients with early onset VAP is 36%, late onset VAP is 63.4%.This is 
because probability of getting VAP increases with the duration of mechanical ventilation. 
Langer, Mosconi, Cigada, & Mandelli (1989) analyzed the relationship between artificial 
ventilatory support and pulmonary infection in 724 critically ill patients who had received 
prolonged (greater than 24 h) ventilatory assistance since admission to ICU. They found that 
the risk for VAP increased from 5% in patients receiving one day of respiratory assistance to 
68.8% in patients receiving more than 30 days. 
7. Profile of organism 
The profile of organism in our study as follows gram negative 59%, gram positive 22%, 
polymicrobial 18.3%.  
 The organism cultured in our study in descending order were pseudomonas (31.8%) 
,MRSA(22.7%), polymicrobials(18.4%), acinetobacter(13.6%), klebsiella(9%) proteus(4.5%) 
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reflecting the higher incidence of MDR organisms in patients with VAP, unlike in 
community acquired pneumonia where streptococcus pneumonia is common.  
Study conducted by Faisal Wahid, Naveed Masood, Asadullah Jafri.  Nosocomial pneumonia 
in mechanically ventilated patients Pak Armed Forces Med J Sep showed the following 
profile of organisms including Pseudomonas aeruginosa(26%), Staphylococcus aureus(20%), 
Acinetobacter spp.(9%), Proteus spp. (6%), Haemophilus spp. (6%), Escherichia coli (6%), 
Klebsiella spp. (3%), Streptococcus pneumoniae (3%), Corynebacteria spp. (3%), and 
Polymicrobial flora (9%). 
8. Mortality  
Mortality in our study according to the age distribution is as follows  
     <30 years-14.28% 
    31-60 years-71.42% 
     >60 years-14.28% 
  
 The greater mortality in the age group 31-60 years probably attributed to their   
associated co morbid conditions.  
 
 
 
9. Risk factors 
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The risk factors for VAP found in our study were diabetes mellitus (50%),elderly age group, 
transferring out of ICU(for imaging & special tests),shock in the first 2 days of admission & 
immune compromised status(HIV). 
10 Morbidity 
Patients with VAP had prolonged stay in ICU(10-20 days)unlike in patients without 
VAP(<10 days). The study conducted by Boyce, J. M., G. Potter-Bynoe, L. Dziobek, and S. 
L. Solomon showed an increased ICU lengths of stays (LOS) from 4 to13 days.  Bercault & 
Boulain, 2001; Rello et al., 2002. showed that the development of VAP increases the length 
on the mechanical ventilator by 4 days, critical care and hospital lengths of stay (LOS) by 4 
and 9 days, respectively. 
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CONCLUSION 
1. Method of intubation emergency or elective did not change the incidence of VAP. 
2. The incidence of VAP increases with the duration of mechanical ventilation. 
3. Aspiration is major precipitating factor for developing VAP. 
4. High incidence of MDR organisms in patients with VAP unlike in community 
acquired pneumonia. 
5. Diabetes is one of the major risk factor to develop VAP 
6. Duration of stay in ICU patients with VAP very much pronged unlike in N- VAP . 
 
 
 
 
67 
 
PERFORMA 
Name : 
Age: 
gender:  
Complete diagnosis: 
Duration of mechanical ventilation/ hospitalisation: 
Indication for intubation: 
Emergency/Elective:  
Preventive measures undertaken: 
                  
 
 
 
 
Diagnosis of VAP:    EARLY   /   LATE 
  
                    
              
 
1  Chest X –ray  
2 Temp  
3 TLC  
4 TBA aspirate  
  
                      
 
 
Positioning  
Suctioning  
Oral care  
Antibiotics  
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Others: 
ECG- 
ABG- 
CT Chest- 
Treatment: 
Outcome: 
CBC RFT LFT URINE 
Hb Sugar TB Albumin  
TC Urea DB Sugar 
DC Creatinine SGOT deposits 
ESR Na+ SGPT Pus cells 
platelets K+ ALP  organisms 
PCV Blood 
culture 
Total 
protein/albumin 
Urine culture 
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1 Babu 54 M OPC R/P EM DM 8 
R - LL 
Infiltrates 
2 Vijayakumar 60 M CVA(H) Poor GCS EL 
DM/H/o 
Transfe 6 
R - M/LL 
Infiltrates 
3 Arun 28 M Snake Bite (N) R/P EM - 4 - 
4 Charles 45 M DCLD/HRS Shock EM Shock 3 - 
5 Divya 19 F Puerperal Sepsis Shock EM Shock 5 
L - LL 
infiltrates 
6 Kalyani 44 F Oleander 
Cardio 
Respiratory 
Arrest EM - 2 - 
7 Kannan 68 M CVA(H) Poor GCS EM 
DM/Old 
Age 3 - 
8 Raja 36 M Seizure disorder Status EM - 4 
R - LL 
Infiltrates 
9 Arulkumar 28 M 
CKD/Pulmonary 
Edema 
Pulmonary 
Edema EM - 5 
R & L - LL 
infiltrates 
10 Murugan 24 M GBS 
Respiratory 
paralysis EL - 30 
L - LL 
infiltrates 
11 Shankar 37 M DM/DKA Poor GCS EL DM 14 
R - LL 
Infiltrates 
12 Velu 30 M Hupokalemic PP 
Respiratory 
paralysis EL - 15 
R - LL 
Infiltrates 
13 Karthick 32 M Snake Bite (N) 
Respiratory 
paralysis EM - 13 
L - LL 
infiltrates 
14 Devaraj 40 M Myasthenia Gravis 
Myasthenic 
Crisis EM - 17 
R - UZ 
infiltrates 
15 Sadhasivam 20 M OPC R/P EM - 10 
R - UZ 
infiltrates 
16 Dhanalakshmi 61 F 
Acute CVA, 
RHD/MS/MR 
AS (past CMC) Poor GCS EL DM 11 
R - LZ 
inflitrates 
17 Pachiammal 50 F ADD/ARF/Sepsis Shock EM Shock 9 
R - UL/MZ 
infiltrates 
18 Latha 22 F Super valmet Hemi R/P EM - 65 
R - UL 
infiltran 
19 Gowri 19 F 
Mental retardation,  
Seizure Status EL - 8 
L - UZ 
infiltran 
20 Anuradha 16 F GBS 
Respiratory 
paralysis EL - 10 
R - LL 
Infiltrates 
21 Alavudeen 48 M 
CAD/Active 
MI/Cardiogenic shock Shock EM Shock 3 
B/L LL 
Infiltrates 
22 Sakthivel 56 M Acute Hepatic Failure Poor GCS EM - 4 - 
23 Vignesh 26 M GBS 
Respiratory 
paralysis EL - 20 
R ML/LL 
and 
L LL 
Infiltrate 
24 Balamurali 38 M Snake Bite (N) 
Respiratory 
Failure EM - 3 - 
25 Latha 34 F Anticonvulsant Tablet Poor GCS EL - 3 R ML 
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1 + 16800 NP N Pseudomonai 1 E 168/46/1.1 Resp.ALK - 20 R 
2 + 8900 P - Polymicrobial 1 E 206/54/1.8 Resp.ALK - 18 D 
3 + 10000 NP - - 0 - 106/40/0.8 - - 10 R 
4 + 11800 NP - - 0 - 66/106/2.0 Met Acid - 5 D 
5 - 10800 NP - - 0 - 78/66/2.4 Met Acid - 8 D 
6 - 8000 NP - - 0 - 148/48/1.4 - - 3 D 
7 - 11800 NP - - 0 - 298/48/3.4 Met Acid - 5 D 
8 + - NP - - 0 - 102/36/0.6 Resp.ALK - 8 R 
9 + 9600 NP - - 0 - 356/94/3.6 Met Acid - 6 D 
10 + 13800 P N Pseudo 1 L 124/36/1.2 Resp.ALK - 30 D 
11 + 14240 P P MRSA 1 L 146/76/2.0 Met ALK - 16 R 
12 + 14100 NP N - 0 - 446/80/2.1 Resp.ALK - 20 R 
13 + 9200 P N Pseudo 1 L 68/26/0.9 Met Acid - 15 R 
14 + 12100 P N Klebsicella 1 L 206/19/0.9 - BAL 23 R 
15 + 16200 NP N Pseudo 1 L 124/36/1.1 Resp.ALK - 25 D 
16 + 10400 P - Polymicrobial 1 L 105/57/1.3 - - 31 D 
17 + 10740 P N Acinetobacter 1 E 139/45/1 - - 9 D 
18 + 10400 P P MRSA 1 L 123/18/0.6 - - 70 R 
19 + 11300 P N Pseudomonas 1 E 62/15/0.5 - - 13 R 
20 + 16080 P N Acinetobacter 1 L 98/40/1.2 Resp.ALK - 56 R 
21 - 12100 NP - - 0 - 168/48/1.5 Met Acid - 3 D 
22 - 8900 NP - - 0 - 86/68/1.4 Met Acid - 5 D 
23 + 10800 P N Klebsicella 1 L 106/46/1.2 Resp.ALK - 40 R 
24 - 6800 NP - - 0 - 104/32/0.8 - - 7 R 
25 - 11800 NP - - 0 - 124/34/0.8 Met Acid - 5 R 
overdosage Infiltrate 
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26 Barathi 24 F RHD/MS/MR/AF/PHT Pulmonary Edema EM - 4 
B/L Base 
Infiltrate 
27 Ganesan 72 M CVA(H) Poor GCS EM 
DM/Old 
Age/ 
Transfer 
out 4 L - LL infiltrates 
28 Sridhar 42 M TBM/Hydrolephalus Poor GCS EL HIV 5 
B/L - LL 
Infiltrate 
29 Ramesh 48 M 
DCLD/Hepatic 
Encephalopathy Poor GCS EM - 7 - 
30 Selvaraj 62 M Metabolic Encephalopathy Respiratory arrest EM DM 4 - 
31 Kumar 39 M Hanging/HIE 
Respiratory 
Failure EM - 10 L - UL Infiltrate 
32 Anandhan 58 M CAD/CCF/Shock/DM/CKD Poor GCS EM shock/DM 8 R - ML Infiltrate 
33 Shankar 32 M GBS 
Respiratory 
Weakness EL - 18 
B/L - LL 
Infiltrate 
34 Ravi 18 M 
Anticonvulsant Tablet 
overdosage Poor GCS EM - 4 - 
35 Palani 52 M Glioma R Frontal Lobe Status epilepticus EM - 6 - 
36 Rajan 48 M Seizure disorder Status EM - 3 - 
37 Latha 32 F SLE/Lupus Nephritis Poor GCS EM - 4 - 
38 David 72 M CVA(I) Poor GCS EM - 3 - 
39 Madhu 52 M ARF/Leptospirosis Shock EM Shock 4 L - LL infiltrate 
40 Mary 48 F Viral Encephalitis Status EM - 12 R - LL Infiltrate 
41 Vishnulingam 58 M GBS/DM 
Respiratory 
paralysis EL DM 28 R - LL Infiltrate 
42 Kalaiselvi 42 F Hypothyrodism/DCM Coma EM - 6 - 
43 Patchiammal 58 F 
DM/SHT/Metabolic 
Encephalopathy Poor GCS EM DM 8 R - LL Infiltrates 
44 Rajaram 14 M Scorpion sting 
Shock/Pulmonary 
Edema EM - 3 - 
45 Pitchai 42 M 
HBS AG +ve/Postnecrotic  
cirrhosis/HE Poor GCS EM - 8 
R - ML/LL 
Infiltrate 
46 Karunakaran 30 M GBS 
Respiratory 
paralysis EL - 16 
R - LL/L - LL 
Infiltrate 
47 Muthukumar 46 M DCLD/SBP Shock EM Shock 4 - 
48 Ilayaraja 52 M DM/L Pyelonephritis shock EM Shock 8 - 
49 Stella 66 F CVA (H) / DM Poor GCS EM DM 5 
R - ML/LL 
Infiltrate 
50 Saravanan 38 M Snake Bite (N) 
Respiratory 
paralysis EL - 3 - 
26 - 10800 NP - - 0 - 96/28/0.6 Met Acid - 4 D 
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27 - 9200 P - - 0 - 196/56/1.6 - - 4 D 
28 + 6800 P N Acinetobacter 1 E 86/32/1.0 Resp.ALK - 5 D 
29 - 11800 NP - - 0 - 136/48/1.2 - - 7 D 
30 - 12600 NP - - 0 - 192/56/2.4 - - 5 D 
31 + 10800 P - Polymicrobial 1 L 118/32/0.8 - - 25 R 
32 - 9600 NP - - 0 - 116/56/3.2 - - 8 D 
33 + 14600 P N Proteus 1 L 108/42/1.2 Resp.ALK - 30 R 
34 + 11400 NP - - 0 - 124/36/0.6 Met Acidosis - 7 R 
35 - 7200 NP - - 0 - 108/42/1.2 - - 6 D 
36 + 10800 NP - - 0 - 158/32/1.0 Resp.ALK - 7 R 
37 + 9600 NP - - 0 - 168/68/5.6 - - 6 D 
38 - 10800 NP - - 0 - 108/42/1.2 - - 4 D 
39 - 18600 NP - - 0 - 96/48/3.2 
Metabolic 
Alkalaosis - 4 D 
40 + 20400 P N Pseudomonas 1 L 112/32/1.2 - 
LP  
Lymphocytosis  18 R 
41 + 16200 P P MRSA 1 L 302/48/1.8 - - 42 R 
42 - 9600 NP - - 0 - 102/44/0.6 
Metabolic 
Alkalaosis T3 ↓ T4 ↓  10 D 
43 + 12600 P P MRSA 1 E 102/32/1.8 - - 10 D 
44 - 10200 NP - - 0 - 142/32/1.0 - - 6 R 
45 + 10800 P N Pseudomonas 1 E 86/52/1.8 
Metabolic 
Alkalaosis - 9 D 
46 + 12800 P - Polymicrobial 1 L 136/42/0.8 - - 28 D 
47 + 12200 NP - - 0 - 108/56/0.8 
Metabolic 
Alkalaosis - 4 D 
48 + 14600 NP - - 0 - 288/72/2.8 
Metabolic 
Alkalaosis - 9 D 
49 + 13800 P P MRSA 1 E 156/48/1.8 - - 5 D 
50 - 9600 NP - - 0 - 124/40/0.8 - - 6 D 
 
